Name
Mutagens
Accession Number
DBCAT000955
Description

Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.

Drugs
DrugDrug Description
CyclophosphamideA nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.
DantronA drug used to relieve acute and chronic inflammation of the oral cavity and oropharynx.
LacidipineA lipophilic dihydropyridine calcium channel blocker with a slow onset of action used to treat hypertension.
HydroquinoneA topical brightening agent used for the treatment of skin disorders associated with hyperpigmentation including melasma, post-inflammatory hyperpigmentation, sunspots, and freckles.
AminacrineA slow-acting germicide effective against bacteria and fungi which is included in drug formulations for its anti-septic properties.
BenznidazoleA trypanocidal agent used to treat Chagas disease.
CordycepinCordycepin has been used in trials studying the treatment of Leukemia.
TrofosfamideTrofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.
CarbendazimCarbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.
ThiramThiram may be used in dermatology as a scabicide . Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for...
Sodium bisulfiteAn ingredient in parenteral nutrition products for patients with severe liver disorders.
p-AminophenolNot Annotated
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridinePhIP (2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine) has been used in trials studying the basic science of Pancreas Cancer.
PatulinNot Annotated
EmoxypineEmoxypine is under investigation in clinical trial NCT06221826 (MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure).
Drugs & Drug Targets
DrugTargetType
CyclophosphamideDNAtarget
CyclophosphamideCytochrome P450 2B6enzyme
CyclophosphamideCytochrome P450 2C9enzyme
CyclophosphamideCytochrome P450 3A4enzyme
CyclophosphamideCytochrome P450 2C19enzyme
CyclophosphamideCytochrome P450 2A6enzyme
CyclophosphamideCytochrome P450 2C18enzyme
CyclophosphamideCytochrome P450 2C8enzyme
CyclophosphamideCytochrome P450 3A5enzyme
CyclophosphamideNuclear receptor subfamily 1 group I member 2target
DantronAlbumincarrier
LacidipineCytochrome P450 3A4enzyme
LacidipineAlbumincarrier
LacidipineAlpha-1-acid glycoprotein 1carrier
LacidipineVoltage-dependent L-type calcium channeltarget
HydroquinoneTyrosinasetarget
HydroquinoneAlbumincarrier
HydroquinoneLysosomal alpha-glucosidaseenzyme
HydroquinoneCysteinyl leukotriene receptor 1target
HydroquinoneIntegrin alpha-IIbtarget
HydroquinoneIntegrin beta-3target
CarbendazimAromataseenzyme
CarbendazimAryl hydrocarbon receptortarget
ThiramTyrosine-protein kinase JAK2target
p-AminophenolCarbonic anhydrase 14target
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridineEstrogen receptortarget
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridineNuclear receptor coactivator 2target
PatulinGenome polyproteintarget